Seminars in Oncology
Volume 33 , Pages 15-21 , June 2006

Cardiotoxic Consequences of Anthracycline-Containing Therapy in Patients With Breast Cancer

  • Benny Vittrup Jensen

      Affiliations

    • Dr Jensen has served as a speaker for Chiron Biopharmaceuticals.
    • Corresponding Author InformationAddress reprint requests to Benny Vittrup Jensen, MD, Department of Oncology, University Hospital of Copenhagen, 2730 Herlev, Denmark.

References 

  1. American Cancer Society Facts and Figures 2006. Available at: http://www.cancer.org/docroot/STT/stt_0.asp (accessed April 13, 2006)
  2. La Vecchia C , Lucchini F , Negri E , et al.  Trends of cancer mortality in Europe, 1955-1989 (III, Breast and genital sites) . Eur J Cancer . 1992;28A:927–998
  3. La Vecchia C , Lucchini F , Negri E , et al.  Trends in cancer mortality in the Americas, 1955-1989 . Eur J Cancer . 1993;29A:431–470
  4. National Cancer Institute. Cancer Facts 5.6. Available at: http://www.cancer.gov/cancertopics/factsheet/Detection/probability-breast-cancer (accessed April 13, 2006)
  5. Jensen BV , Skovsgaard T , Nielsen SL . Functional monitoring of anthracycline cardiotoxicity (A prospective, blinded, long-term observational study of outcome in 120 patients) . Ann Oncol . 2002;13:699–709
  6. Slamon DJ , Leyland-Jones B , Shak S , et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 . N Engl J Med . 2001;344:783–792
  7. Gluck S . The expanding role of epirubicin in the treatment of breast cancer . Cancer Control . 2002;9:16–27
  8. Early Breast Cancer Trialists’ Collaborative Group . Polychemotherapy for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group . Lancet . 1998;352:930–942
  9. Early Breast Cancer Trialists’ Collaborative Group . Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival (An overview of the randomised trials) . Lancet . 2005;365:1687–1717
  10. Piccart-Gebhart MJ , Procter M , Leyland-Jones B , et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer . N Engl J Med . 2005;353:1659–1672
  11. Romond EH , Perez EA , Bryant J , et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer . N Engl J Med . 2005;353:1673–1684
  12. Danish breast cancer group (DBCG) 2004: Facts and figures 2004. Available at http://www.dbcg.dk/PDF%20Filer/Informationsbladet%202004.pdf (accessed April 13, 2006)
  13. Ryberg M , Nielsen D , Skovsgaard T , et al.  Epirubicin cardiotoxicity (An analysis of 469 patients with metastatic breast cancer) . J Clin Oncol . 1998;16:3502–3508
  14. Sledge GW , Neuberg D , Bernardo P , et al.  Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer (An intergroup trial (E1193)) . J Clin Oncol . 2003;21:588–592
  15. Von Hoff DD , Layard MW , Basa P , et al.  Risk factors for doxorubicin-induced congestive heart failure . Ann Intern Med . 1979;91:710–717
  16. Bonadonna G , Valagussa P , Moliterni A , et al.  Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer (The results of 20 years of follow-up) . N Engl J Med . 1995;332:901–906
  17. Minotti G , Menna P , Salvatorelli E , et al.  Anthracyclines (Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity) . Pharmacol Rev . 2004;56:185–229
  18. Bulkley GB . Reactive oxygen metabolites and reperfusion injury (Aberrant triggering of reticuloendothelial function) . Lancet . 1994;344:934–936
  19. Church DF , Pryor WA . Free-radical chemistry of cigarette smoke and its toxicological implications . Environ Health Perspect . 1985;64:111–126
  20. Abraham R , Basser RL , Green MD . A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy . Drug Saf . 1996;15:406–429
  21. Swain SM , Whaley FS , Ewer MS . Congestive heart failure in patients treated with doxorubicin (A retrospective analysis of three trials) . Cancer . 2003;97:2869–2879
  22. Haq MM , Legha SS , Choksi J , et al.  Doxorubicin-induced congestive heart failure in adults . Cancer . 1985;56:1361–1365
  23. Seidman A , Hudis C , Pierri MK , et al.  Cardiac dysfunction in the trastuzumab clinical trials experience . J Clin Oncol . 2002;20:1215–1221
  24. Krischer JP , Epstein S , Cuthbertson DD , et al.  Clinical cardiotoxicity following anthracycline treatment for childhood cancer (The Pediatric Oncology Group experience) . J Clin Oncol . 1997;15:1544–1552
  25. Lipshultz SE , Colan SD , Gelber RD , et al.  Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood . N Engl J Med . 1991;324:808–815
  26. Shan K , Lincoff AM , Young JB . Anthracycline-induced cardiotoxicity . Ann Intern Med . 1996;125:47–58
  27. Steinherz LJ , Steinherz PG , Tan CT , et al.  Cardiac toxicity 4 to 20 years after completing anthracycline therapy . JAMA . 1991;266:1672–1677
  28. Ritchie JL , Bateman TM , Bonow RO , et al.  Guidelines for clinical use of cardiac radionuclide imaging. Report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Radionuclide Imaging), developed in collaboration with the American Society of Nuclear Cardiology . J Am Coll Cardiol . 1995;25:521–547
  29. Perez EA , Suman VJ , Davidson NE , et al.  Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial . J Clin Oncol . 2004;22:3700–3704
  30. The CONSENSUS Trial Study Group . Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group . N Engl J Med . 1987;316:1429–1435
  31. Jensen BV , Nielsen SL , Skovsgaard T . Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy . Lancet . 1996;347:297–299
  32. Henderson IC , Sloss LJ , Jaffe N , et al.  Serial studies of cardiac function in patients receiving adriamycin . Cancer Treat Rep . 1978;62:923–929
  33. Isner JM , Ferrans VJ , Cohen SR , et al.  Clinical and morphologic cardiac findings after anthracycline chemotherapy. Analysis of 64 patients studied at necropsy . Am J Cardiol . 1983;51:1167–1174

PII: S0093-7754(06)00210-7

doi: 10.1053/j.seminoncol.2006.04.022

Seminars in Oncology
Volume 33 , Pages 15-21 , June 2006

Article Tools

* Image Usage & Resolution